New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
09:47 EDTTEVA, PG, ACTTeva announces new organizational structure, senior leadership changes
Teva Pharmaceutical Industries announced a new organizational structure and related executive positions, which will become effective July 1. These changes are another key step in Teva's strategic direction to create a less complex, integrated company that can address the evolving needs of patients in the global markets in the most efficient, innovative and differentiated manner possible, the company said. Teva will be spearheaded by two commercial business units – Global Specialty Medicines, established in April 2013, and the newly-formed Global Generic Medicines group. GGM will have full global responsibility for all existing generic markets. GGM will also be responsible for Teva's growing Over-the-Counter (OTC) business, led by Teva's joint venture with Procter and Gamble (PG). Teva announced that Sigurdur Olafsson has been appointed President and CEO of the newly formed Global Generic Medicines group and will assume this position on July 1, based in the U.S. Olafsson joins Teva from his previous role as President of Actavis Pharma (ACT). GSM, led by Dr. Rob Koremans, is responsible for Teva's global specialty medicines business and will continue to drive organic growth, with a strong pipeline of patient-centric solutions and new brands.
News For TEVA;PG;ACT From The Last 14 Days
Check below for free stories on TEVA;PG;ACT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 23, 2014
08:10 EDTTEVA, ACTDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
16:08 EDTTEVATeva initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
July 18, 2014
12:21 EDTPGCable ad upfront volumes may drop 4% or more, WSJ says
Two of the U.S.'s biggest marketers, Procter & Gamble (PG) and General Motors (GM), have pulled back on their TV network advertising commitments in advance of the "upfront" selling season for cable networks, said The Wall Street Journal, citing people familiar with the matter. The overall volume of ad dollars committed to cable networks during the upfront, which is still under way, could be down 4% or more from last year, people familiar with the situation said. Notable owners of cable television stations include 21st Century Fox (FOXA), Time Warner (TWX), Disney (DIS), CBS (CBS), Comcast (CMCSA), Discovery (DISCA), Viacom (VIAB), and AMC Networks (AMCX). The report added that cutbacks partly reflect a shift of tv ad budgets to digital media, including online video. Google (GOOG) has a large presence in online video with YouTube and Facebook (FB) is taking steps to grow in the area. Reference Link
July 17, 2014
15:42 EDTACTDepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information
07:45 EDTPGAs Americans age, Procter & Gamble returns to adult diaper market, WSJ says
Procter & Gamble (PG) is expected in the coming months to re-enter the North American adult diaper market that it had exited over a decade ago, according to The Wall Street Journal, citing several retailers and analysts. Rival Kimberly-Clark's (KMB) CEO recently told investors at a conference that demand for its Huggies training pants has been weakening while sales of incontinence products have been growing steadily, the report noted. Reference Link
July 16, 2014
11:28 EDTACTLeon Cooperman gives 12 stock picks at CNBC conference
Subscribe for More Information
11:16 EDTACTCooperman lists Actavis, Citigroup, KKR among top-picks, CNBC says
Subscribe for More Information
09:12 EDTACTLeerink healthcare analyst holds an analyst/industry conference call
Subscribe for More Information
08:48 EDTTEVATeva says ISS supports company's nominees, shareholders' meeting proposals
Subscribe for More Information
July 15, 2014
16:19 EDTPGStepan subsidiary to acquire sulfonation facility in Brazil
Subscribe for More Information
11:13 EDTTEVAPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
06:28 EDTTEVAActivist shareholder says Teva to appoint new chairman, Reuters says
Subscribe for More Information
July 14, 2014
08:04 EDTTEVATeva announces FDA acceptance of NDA filing for albuterol MDPI
Teva Pharmaceuticals Industries announced that the U.S. Food and Drug Administration has accepted for review the company’s new drug application for albuterol multi-dose dry-powder inhaler, an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents with asthma and exercise-induced bronchospasm. The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.
July 11, 2014
16:31 EDTACTActavis confirms generic Diclegis patent challenge
Subscribe for More Information
10:00 EDTPGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:44 EDTPGProcter & Gamble downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded its rating on Procter & Gamble (PG) shares to Market Perform citing a lack of lack of fundamental progress despite the company's increased innovation. Wells says P&G's U.S. share trends have weakened amid competition. The firm cut its price target range for shares to $85-$87 from $88-$90.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use